DBV Technologies S.A. (NASDAQ: DBVT) is committed to finding a safe, effective and patient-friendly therapy for food and pediatric allergy patients, for whom there are no currently approved treatments. The company has a proprietary platform based on its epicutaneous Viaskin patch, an electrostatic patch which offers a convenient, self-administered, non-invasive immunotherapy to patients. The company has designed and developed this technology internally; however, it has scalable manufacturing capabilities. For more information, visit the company’s website at www.dbv-technologies.com.